Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 2.8 years of cash runway.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$696M | — | — | -$144M | — | $396M |
| 2024 | — | -$117M | — | — | -$100M | — | $82M |
| 2023 | — | -$118M | — | — | -$101M | — | $31M |
| 2022 | — | -$92M | — | — | -$94M | — | $58M |
| 2021 | — | -$69M | — | — | -$73M | — | $120M |
| 2020 | — | -$43M | — | — | -$40M | — | $49M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$220M | — | — | -$38M | — | $170M |
| Dec '25 | — | $1.7B | — | — | -$23M | — | $396M |
| Sep '25 | — | -$813M | — | — | -$54M | — | $160M |
| Jun '25 | — | -$1.6B | — | — | -$35M | — | $191M |
| Mar '25 | — | -$32M | — | — | -$31M | — | $50M |
| Dec '24 | — | -$31M | — | — | -$24M | — | $82M |
| Sep '24 | — | -$28M | — | — | -$23M | — | $53M |
| Jun '24 | — | -$28M | — | — | -$22M | — | $76M |
| Mar '24 | — | -$31M | — | — | -$31M | — | $45M |
| Dec '23 | — | -$26M | — | — | -$24M | — | $31M |
| Sep '23 | — | -$33M | — | — | -$28M | — | $45M |
| Jun '23 | — | -$30M | — | — | -$24M | — | $32M |
| Mar '23 | — | -$28M | — | — | -$24M | — | $42M |
| Dec '22 | — | -$24M | — | — | -$19M | — | $58M |
| Sep '22 | — | -$24M | — | — | -$19M | — | $61M |
| Jun '22 | — | -$22M | — | — | -$31M | — | $63M |
| Mar '22 | — | -$23M | — | — | -$25M | — | $90M |
| Dec '21 | — | -$18M | — | — | -$19M | — | $120M |
| Sep '21 | — | -$19M | — | — | -$18M | — | $143M |
| Jun '21 | — | -$18M | — | — | -$17M | — | $170M |
See the revenue and net-income charts above for Vor Biopharma Inc.'s multi-year trend.
As of FY2025, Vor Biopharma Inc. reported — of total debt against $396M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.